Japan, South Korea, and the United Kingdom (notably Moorfields Eye Hospital and other major research centres) are leading in human retinal cell-therapy trials. Switzerland offers private treatment at premium cost (€12,000–20,000). The United States has active research programmes but limited commercial availability.
Cell therapy for macular degeneration remains expensive and largely experimental. Treatment costs range from €6,000 to €15,000+ per eye, reflecting iPSC derivation, long-term cell expansion, quality-control testing, and the technical complexity of subretinal or intravitreal injection. Baseline and follow-up imaging (optical coherence tomography [OCT], visual field testing, electroretinography) adds €2,000–4,000. The condition typically affects both eyes, so bilateral treatment approaches €15,000–30,000.
Sunt un candidat? → · Macular Degeneration & Vision: full overview → · Cost Degenerare Maculară și Vedere → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită